Key terms
About ZLAB
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ZLAB news
Apr 11
7:35am ET
Executive officers of Zai Lab ‘do not anticipate selling any shares’ in 2024
Apr 09
6:20am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Apr 01
7:39am ET
Zai Lab, Bristol Myers: Krazati confirmatory trial meets PFS primary endpoints
Mar 27
9:36am ET
Zai Lab says partner Novocure’s Phase 3 trial met primary endpoint
Mar 01
12:59am ET
Buy Rating Affirmed for Zai Lab Amidst Strong Growth and Positive Future Outlook
Feb 29
6:38am ET
Buy Rating on Zai Lab with a Target Price of $66 Amid Vyvgart’s Growth Potential and Strategic Positioning
Feb 29
6:24am ET
Zai Lab price target lowered to $66 from $123 at Citi
Feb 29
1:03am ET
Zai Lab Ltd’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
Feb 28
6:59am ET
Buy Rating Affirmed for Zai Lab on Strong Product Performance and Upbeat Revenue Projections
Feb 28
5:36am ET
Zai Lab’s Growth and Pipeline Prompts Buy Rating: Analyst David Li’s Financial Outlook and Price Objective
Feb 27
4:40pm ET
Zai Lab reports FY23 EPS (35c), consensus ($3.15)
Feb 21
9:26am ET
Zai Lab price target lowered to $31 from $37 at BofA
Feb 21
5:31am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Globus Medical (GMED) and Zai Lab (ZLAB)
Feb 09
5:03am ET
Zai Lab Secures Debt Facilities to Boost Capital Flexibility
Feb 05
7:55am ET
Zai Lab management to meet with Cantor Fitzgerald
Feb 05
4:55am ET
Zai Lab management to meet with Cantor Fitzgerald
Jan 31
7:53am ET
Zai Lab management to meet with Cantor Fitzgerald
Jan 27
12:07pm ET
Zai Lab price target lowered to $44 from $66 at JPMorgan
Jan 24
1:44am ET
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Arcus Biosciences (RCUS) and Zai Lab (ZLAB)
No recent press releases are available for ZLAB
ZLAB Financials
Key terms
Ad Feedback
ZLAB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ZLAB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
